Blog

Trends and know-how in biotech and downstream purification.

Join the effort to make chromatography sustainable

The environmental impact of pharmaceutical R&D and production is considerable. Although the industry is rather conservative and also constrained by regulatory guidelines, there is increasing interest...

QuickTip #3: optimizing mAb purification

Designing an optimized purification process means maximizing yield and purity, and at the same time controlling costs. So, you remove a lot of bulk impurities during the first steps, and focus on...

Affordable and safe biosimilars for affordable healthcare

When it comes to many serious and challenging diseases, healthcare has reached a point of unsustainability, due to drug costs. For example, sustained therapy for an autoimmune disease or cancer,...

Are mAbs the ultimate targeted therapy?

Since the 1980’s, monoclonal antibodies (mAbs) have revolutionized healthcare and continue to do so. A short history of mAb approvals shows their increasing sophistication and targeting of disease...

QuickTip #2: choosing IEX resin

Recovery of your biologically active target substance is a priority, and it’s important to check for its pH and ionic strength stability values...

CHO cells in fed-batch bioreactors dominate mAb upstream processes

Choosing a mammalian cell line or other type of host is as critical a question as any other in the complex world of monoclonal antibody (mAb) manufacture. We take a look at the present status, with...

QuickTip #1: cleaning IEX columns

When an IEX resin has been used for some time, impurities may build up in the column causing loss of resolution or increase in back pressure (shown on the pressure monitor or seen by gap formation on...

Illnesses with approved monoclonal antibody therapies

As our understanding of diseases at the molecular level increases, so does the potential for monoclonal antibody (mAb) - related therapies. Platform approaches to mAb production, including...

mAb Purification – an overview of the essentials

Five of the top ten best selling drugs in 2017 were mAbs and the global mAbs market is expected to reach USD 219 billion by the end of 2023. The mAbs entering the clinic today are highly engineered...

Optimizing mAb purification with next generation protein A resin

The market for monoclonal antibodies (mAbs) is constantly growing as mAb therapies are generally considered to be both safe and effective treatments for difficult diseases like cancer and rheumatoid...

1
2
3
4
5
6
7 (current)
8